ISCA, CHRYSTEL
 Distribuzione geografica
Continente #
NA - Nord America 1.562
EU - Europa 1.275
AS - Asia 368
AF - Africa 19
SA - Sud America 9
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 3.244
Nazione #
US - Stati Uniti d'America 1.550
IT - Italia 498
IE - Irlanda 266
SE - Svezia 126
GB - Regno Unito 119
CN - Cina 98
DE - Germania 81
HK - Hong Kong 61
FR - Francia 39
SG - Singapore 39
IN - India 32
FI - Finlandia 31
TR - Turchia 23
LT - Lituania 22
BG - Bulgaria 20
TW - Taiwan 20
EG - Egitto 18
JP - Giappone 17
ID - Indonesia 16
VN - Vietnam 15
IQ - Iraq 14
BE - Belgio 13
CZ - Repubblica Ceca 12
MY - Malesia 12
UA - Ucraina 12
CA - Canada 11
AU - Australia 7
ES - Italia 6
KR - Corea 6
NL - Olanda 5
EU - Europa 4
PK - Pakistan 4
PL - Polonia 4
AR - Argentina 3
AT - Austria 3
BR - Brasile 3
RO - Romania 3
RU - Federazione Russa 3
CL - Cile 2
GR - Grecia 2
IR - Iran 2
IS - Islanda 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CH - Svizzera 1
ET - Etiopia 1
HR - Croazia 1
MX - Messico 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
Totale 3.244
Città #
Chandler 270
Dublin 263
Fairfield 185
Ashburn 134
Nyköping 101
Southend 79
Woodbridge 73
Houston 71
Ann Arbor 65
Seattle 64
Hong Kong 60
Wilmington 57
Cambridge 53
Dearborn 43
New York 41
Modena 37
Beijing 31
Helsinki 31
Milan 31
Fremont 28
Bologna 27
Redwood City 27
San Diego 25
Princeton 22
Singapore 22
Sofia 20
Asyut 18
Bremen 17
Rome 17
Jakarta 16
San Giuliano Milanese 16
Shanghai 16
Baghdad 14
Banqiao 14
Dong Ket 14
Jacksonville 13
Parma 13
Eugene 12
Tokyo 11
Des Moines 10
Falls Church 10
Izmir 10
Brno 9
Brussels 9
Castelvetrano 9
Sassuolo 9
Absecon 8
London 8
Paris 7
Santorso 7
Genoa 6
Palermo 6
Venezia 6
Vicenza 6
Amsterdam 5
Boardman 5
Bomporto 5
Carpi 5
Changchun 5
Chicago 5
Longiano 5
Los Angeles 5
Munich 5
Mykolayiv 5
Savona 5
Sydney 5
Toronto 5
Florence 4
Guangzhou 4
Lüleburgaz 4
Madrid 4
Marseille 4
Mesagne 4
Norwalk 4
Reggio Emilia 4
San Marco 4
Sant'Ilario d'Enza 4
Ankara 3
Bari 3
Breganze 3
Brooklyn 3
Chiswick 3
Coral Springs 3
Forlì 3
Frankfurt am Main 3
Grafing 3
Gunzenhausen 3
Hangzhou 3
Hyderabad 3
Istanbul 3
Maruggio 3
Monza 3
North Wales 3
Padova 3
Presezzo 3
Saludecio 3
Scandiano 3
Sint-pieters-leeuw 3
Taipei 3
Voghera 3
Totale 2.345
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 371
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 243
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 214
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 202
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 182
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 176
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 147
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 145
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 144
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 143
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 124
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 124
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 123
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 121
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 111
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 108
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 102
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 101
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 96
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 93
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. 65
Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: A single institutional retrospective report 56
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 47
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 29
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 21
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 12
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 4
Totale 3.304
Categoria #
all - tutte 12.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.912


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020376 17 22 13 45 43 68 55 27 29 16 22 19
2020/2021546 45 59 24 65 72 39 15 44 43 53 13 74
2021/2022551 57 42 33 29 22 51 22 25 50 56 98 66
2022/20231.019 83 126 64 85 81 82 16 71 316 29 33 33
2023/2024617 28 26 52 66 59 75 78 58 33 30 56 56
2024/202535 35 0 0 0 0 0 0 0 0 0 0 0
Totale 3.304